For CCL14 values > 13 ng/mL, all participants agreed or somewhat agreed that these levels can help identify patients at the highest risk of developing PS-AKI who could be candidates for increased prioritization of AKI management and care processes. This evidence concerns the gene CCL14 and acute kidney injury.